This report covers the 7MM (US, France, Germany, Italy, Spain, UK, Japan) and provides an Excel-based forecast model for the Migraine market through 2033.
The analyst estimates that the value of the migraine market in the 7MM in 2023 was $9.2 billion. This market is defined as sales of acute and preventatitve treatments including widely used triptans and ergot alkaloids used in abortive treatment amongst others as well as oral preventive therapies such as antidepressants, anticonvulsants, and beta blockers and the newer CGRP-targeting mAbs or gepants across the 7MM. Among these sales, $7.5 billion (81.5%) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated $1.5 billion (15.9%). Japan generated the lowest sales, with an estimated $241 million (2.6%).
By the end of the forecast period in 2033, The analyst projects female infertility sales to rise to $16.4 billion in the 7MM, at a modest compound annual growth rate (CAGR) of 6.0%.
The analyst estimates that the value of the migraine market in the 7MM in 2023 was $9.2 billion. This market is defined as sales of acute and preventatitve treatments including widely used triptans and ergot alkaloids used in abortive treatment amongst others as well as oral preventive therapies such as antidepressants, anticonvulsants, and beta blockers and the newer CGRP-targeting mAbs or gepants across the 7MM. Among these sales, $7.5 billion (81.5%) were generated in the US, with the 5EU representing the next largest region by sales, with an estimated $1.5 billion (15.9%). Japan generated the lowest sales, with an estimated $241 million (2.6%).
By the end of the forecast period in 2033, The analyst projects female infertility sales to rise to $16.4 billion in the 7MM, at a modest compound annual growth rate (CAGR) of 6.0%.
Scope
- Overview of migraine, including epidemiology, symptoms, diagnosis, and disease management.
- Annualized migraine therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the migraine therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for migraine treatment. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global migraine therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the 7MM migraine therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM migraine therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1 Migraine: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Current Treatment Options
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
12 Market Outlook
13 Appendix
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- GSK
- Dr. Reddy's Laboratories
- OptiNose
- Currax Pharmaceuticals
- Tonix Pharmaceuticals
- AstraZeneca
- Endo Pharmaceuticals
- Almirall
- Viatris
- Bausch Health Companies
- IPI Legacy Liquidation Co
- Supernus Pharmaceuticals
- Upsher-Smith Laboratories
- Sandoz
- Merck & Co
- Mallinckrodt
- AbbVie
- Johnson & Johnson
- Eli Lilly
- Amgen
- Teva Pharmaceutical Industries
- H. Lundbeck AS
- Bristol-Myers Squibb
- Axsome Therapeutics
- Satsuma Pharmaceuticals
- Amneal Pharmaceuticals
- Klaria Pharma
- Ipsen
- Allodynic Therapeutics
- Auden McKenzie
- Lupin
- Orion
